Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Eur J Haematol ; 92(4): 331-6, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24330187

RESUMEN

OBJECTIVE: Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition that clinically characterized by fever, hepatosplenomegaly, and cytopenia. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment option for patients diagnosed with primary HLH. METHODS: In this prospective study, we analyzed the outcome of 10 pediatric patients with primary HLH who had received HSCT, using reduced-intensity conditioning (RIC) regimen from 2007 to 2012. The median age at transplantation was 22.6 months (range: 6-60). All of the patients received the same RIC regimen based on the use of fludarabine in combination with melphalan and horse antithymocyte globulin (ATG). Cyclosporine and methylprednisolone were used as graft-vs.-host disease (GvHD) prophylaxis. RESULTS: Hematopoietic engraftment occurred in all patients. At the present time, 8 patients with a median follow-up of 39 months are still alive and all of them are disease free. Acute and chronic GvHD developed in 6 and 2 patients, retrospectively. Two patients died of sepsis and chronic GvHD during the study. CONCLUSION: Because of pretransplant infections caused by underlying immunodeficiency in patients with primary HLH, the use of less toxic regimen with RIC seems to be highly effective in this regard. Recipients of RIC transplant, with either full or mixed chimerism, had a long-term survival rate with no manifestation of primary HLH symptoms.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Linfohistiocitosis Hemofagocítica/terapia , Acondicionamiento Pretrasplante , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Niño , Preescolar , Femenino , Estudios de Seguimiento , Enfermedad Injerto contra Huésped , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Lactante , Linfohistiocitosis Hemofagocítica/diagnóstico , Masculino , Agonistas Mieloablativos/administración & dosificación , Estudios Prospectivos , Quimera por Trasplante , Resultado del Tratamiento , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados
2.
Pediatr Transplant ; 17(5): 487-91, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23714271

RESUMEN

Partial albinism with variable immunodeficiency are the two major characteristics of Griscelli syndrome type 2 (GS-2). This syndrome is usually associated with a high mortality rate and commonly results in early childhood death. Patients suffer from different infections and experience crisis of HLH. HSCT remains the sole curative treatment for GS-2. We prospectively analyzed the outcomes of transplantation with RIC regimen in five patients. The median age at transplantation was 21.6 months (range: 12-30). All of the patients underwent HSCT from HLA-matched related donors. Currently, four patients are cured, and symptoms of recurrent infections and HLH crisis are not seen in them. The only patient who died had undergone HSCT in the accelerated phase of HLH. One patient who developed acute GvHD had a favorable response to therapy. No chronic GvHD occurred in patients. It seems that the use of RIC regimen as a method of transplant preparation is effective and tolerable in this group of patients with various comorbidities. It is recommended to carry out HSCT in these patients at lower ages, before presentations of different infections and HLH crisis.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Síndromes de Inmunodeficiencia/terapia , Piebaldismo/terapia , Acondicionamiento Pretrasplante/métodos , Preescolar , Estudios de Seguimiento , Enfermedad Injerto contra Huésped , Antígenos HLA/metabolismo , Humanos , Sistema Inmunológico , Lactante , Linfohistiocitosis Hemofagocítica , Masculino , Agonistas Mieloablativos/uso terapéutico , Enfermedades de Inmunodeficiencia Primaria , Estudios Prospectivos , Donantes de Tejidos , Resultado del Tratamiento , Vidarabina/análogos & derivados , Vidarabina/uso terapéutico
3.
Am J Case Rep ; 22: e931772, 2021 Nov 12.
Artículo en Inglés | MEDLINE | ID: mdl-34764233

RESUMEN

BACKGROUND The incidence of multiple primaries in cancer patients is 2-17%. However, the synchronous co-occurrence of adenocarcinoma of the breast and follicular lymphoma is rare. CASE REPORT We describe a case series of 3 post-menopausal women who presented to our institute with a breast lump. On further investigations, 2 of them had invasive ductal carcinoma and 1 had invasive lobular carcinoma of the breast. All 3 cancers were estrogen/progesterone receptor (ER/PR)-positive and human epidermal growth factor receptor 2 (HER-2)-negative. During the staging PET scans, all 3 patients had increased FDG uptake in axillary, mesenteric, and inguinal lymph nodes, respectively, raising concerns for metastatic disease. However, subsequent biopsies revealed them as follicular lymphomas occurring as a second concurrent primary malignancy. All patients underwent radical mastectomies with sentinel lymph node dissection followed by chemotherapy and hormonal therapy. Most of the lymphomas were low grade, which the oncologist closely followed. CONCLUSIONS Very few cases of breast cancer and follicular lymphoma co-occur; this is not limited to the axillary lymph nodes and can occur in any part of the lymphatic chain. Regional lymph node enlargement detected on examination or imaging does not always indicate metastasis. A high index of suspicion is needed followed by lymph node biopsy to rule out any second primary malignancy.


Asunto(s)
Neoplasias de la Mama , Linfoma Folicular , Axila , Neoplasias de la Mama/cirugía , Femenino , Humanos , Metástasis Linfática , Linfoma Folicular/diagnóstico , Biopsia del Ganglio Linfático Centinela
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA